Medicare GLP-1 Bridge Program to Cover Weight-Management Drugs for 3.8 Million Beneficiaries
A new temporary Medicare program, the GLP-1 Bridge, will provide coverage for weight-reduction medications to 3.8 million beneficiaries starting July 1, 2026, according to a KFF analysis of 2023 claims data. The 18-month initiative, running through December 2027, will include Wegovy, Zepbound, and Foundayo, but eligibility is restricted to those meeting strict clinical criteria.
Eligibility Criteria: BMI and Comorbidities
To qualify, beneficiaries must have a body mass index (BMI) of 35 or higher, or a BMI of 27 or higher with specific comorbid conditions such as hypertension or sleep apnea. Additionally, participants cannot have conditions treated by GLP-1 drugs already covered under Medicare Part D, like type 2 diabetes, and must not have filled a GLP-1 prescription in 2026. These restrictions narrow the eligible population, as only 3.8 million of the 9.7 million Part D enrollees meeting BMI thresholds ultimately qualify.
Cost Projections: $1.3 Billion to $10 Billion Depending on Participation
The program’s federal cost will vary based on participation rates. If 10% to 25% of eligible beneficiaries enroll and fill prescriptions monthly, Medicare could spend $1.3 billion to $3.3 billion. At higher participation rates—50% to 75%—the cost could rise to $6.7 billion to $10 billion. These estimates account for a $50 beneficiary copay per prescription, with the government covering the remaining $245 monthly cost.
Why the Program Matters: Addressing Obesity in Medicare
Obesity affects over 13 million Medicare beneficiaries, but the program’s targeted approach reflects challenges in expanding access to GLP-1 therapies. Unlike broader weight-management initiatives, the Bridge excludes those with diabetes, a group for whom GLP-1s are already covered. This highlights a gap in addressing obesity among Medicare beneficiaries with comorbid conditions, according to the KFF analysis.
How the Program Works: Part D Coverage and Enrollment
The GLP-1 Bridge is a temporary fix to ensure coverage for eligible beneficiaries during a period of limited access to these medications under standard Part D plans. Enrollment will begin in July 2026, with beneficiaries required to meet the criteria at the time of application. The program does not guarantee long-term coverage beyond 2027, leaving questions about future access for participants.
For more details, visit the Centers for Medicare & Medicaid Services (CMS) website or review the KFF analysis.